Compare Chart Industries Inc (GTLS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chart Industries Inc vs BIO-TECHNE Corp — how do they compare? Chart Industries Inc trades at $209.97 (market cap $10.05B), while BIO-TECHNE Corp trades at $71.56 (market cap $11.14B). The key difference: Chart Industries Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| GTLS | TECH | |
|---|---|---|
Market Cap | $10.05B | $11.14B |
Sector | Technology | Health |
52-Week High | $209.91 | $71.48 |
52-Week Low | $167.29 | $43.31 |
Enterprise Value | $13.57B | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GTLS trades at $209.97, up 0.03% on the day, with a bullish technical signal driven by moving averages. The company reported $4.26B revenue for 2025 but missed earnings estimates for three consecutive quarters, with a net income margin of -0.62%. Recent news highlights Baker Hughes' pending $13.6B acquisition, which received conditional EU approval in July 2026.
The outlook is mixed: strong analyst support (54% buy ratings) and acquisition potential offer upside, but weak profitability and earnings misses pose risks. Investors should weigh the acquisition's completion against fundamental challenges in the near term.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
